• Scientific updates on monitor for NKX101 in first half of 2023 and NKX019 in full yr 2023

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical firm creating engineered pure killer (NK) cell therapies to deal with most cancers, immediately introduced that Nadir Mahmood, PhD, has resigned his place as chief monetary and enterprise officer to function the chief government officer of a non-public biotechnology firm. Dr. Mahmood will stay with Nkarta till June 30, 2023, to make sure a clean transition. Nkarta stays on monitor to announce up to date outcomes from its ongoing medical trial of NKX101 within the second quarter of 2023.

“Nadir is a consummate biotech government, revered colleague and cherished buddy,” stated Paul J. Hastings, President and CEO of Nkarta. “It’s clear to me that after practically 5 years of service at Nkarta, he’s prepared and certified to tackle even higher management duties as CEO of his personal group. Whereas this farewell will probably be heartbreaking, we’ll have the nice fortune of Nadir’s involvement with our deliberate NKX101 replace in 2Q 2023. We’re grateful to Nadir for his immeasurable contributions, and we want him success in his subsequent endeavor to deliver modern therapies to sufferers.”

“Nkarta has been a labor of affection that’s given me the chance to study and develop as a frontrunner,” stated Dr. Mahmood. “Transferring to this subsequent stage of my profession has been an especially troublesome determination. My sincerest because of all my Nkarta colleagues, particularly Paul and the Board of Administrators, for his or her help through the years. As I shut out my tenure right here and we put together for the subsequent NKX101 replace, I stay totally dedicated to Nkarta and sit up for the continued progress of its medical applications and pipeline.”

Nkarta has initiated an exterior seek for its subsequent chief monetary officer.

About Nkarta
Nkarta is a clinical-stage biotechnology firm advancing the event of allogeneic, off-the-shelf pure killer (NK) cell therapies for sufferers with most cancers. By combining its cell growth and cryopreservation platform with proprietary cell engineering applied sciences and CRISPR-based genome engineering capabilities, Nkarta is constructing a pipeline of future cell therapies engineered for deep anti-tumor exercise and meant for broad entry within the outpatient remedy setting. For extra data, please go to the corporate’s web site at www.nkartatx.com.

Cautionary Be aware on Ahead-Wanting Statements
Statements contained on this press launch concerning issues that aren’t historic information are “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995, as amended. Phrases reminiscent of “anticipates,” “believes,” “expects,” “intends,” “plans,” “potential,” “initiatives,” “would,” and “future” or related expressions are meant to establish forward-looking statements. Examples of those forward-looking statements embody statements regarding Nkarta’s expectations concerning any or the entire following: the timing of future medical updates for NKX101 and NKX019; the potential influence of Dr. Mahmood’s departure on Nkarta; and Nkarta’s capability to proceed to advance its medical applications and pipelines. As a result of ahead trying statements are topic to dangers and uncertainties, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. These dangers and uncertainties embody, amongst others: Nkarta’s restricted working historical past and historic losses; Nkarta’s lack of any merchandise authorized on the market and its capability to realize profitability; the danger that the outcomes of preclinical research and early-stage medical trials is probably not predictive of future outcomes; Nkarta’s capability to boost extra funding to finish the event and any commercialization of its product candidates; Nkarta’s dependence on the success of its co-lead product candidates, NKX101 and NKX019; that Nkarta could also be delayed in initiating, enrolling or finishing any medical trials; competitors from third events which are creating merchandise for related makes use of; Nkarta’s capability to acquire, keep and shield its mental property; Nkarta’s dependence on third events in reference to sure manufacturing, medical trials, and pre-clinical research; the complexity of the manufacturing course of for CAR NK cell therapies; the provision of parts and provides needed for the conduct of our medical trials; and dangers regarding the influence on Nkarta’s enterprise of the COVID-19 pandemic or related public well being crises.

These and different dangers are described extra totally in Nkarta’s filings with the Securities and Trade Fee (“SEC”), together with the “Danger Components” part of Nkarta’s Annual Report on Kind 10-Ok for the quarter and yr ended December 31, 2022, filed with the SEC on March 16, 2023, and Nkarta’s different paperwork subsequently filed with or furnished to the SEC. All forward-looking statements contained on this press launch communicate solely as of the date on which they had been made. Besides to the extent required by legislation, Nkarta undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date on which they had been made.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
[email protected]